4,4-dimethyl-5-alpha-cholesta-(8,24)-dien-3-beta-ol: RN given refers to (3beta,5alpha)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
14-demethyllanosterol : A 3beta-sterol formed formally by loss of a methyl group from the 14-position of lanosterol. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
ID Source | ID |
---|---|
PubMed CID | 165609 |
CHEBI ID | 18364 |
SCHEMBL ID | 188095 |
MeSH ID | M0061301 |
Synonym |
---|
4,4-dimethylcholesta-8(9),24-dien-3beta-ol |
4,4-dimethylzymosterol |
(3beta,5alpha)-4,4-dimethylcholesta-8,24-dien-3-ol |
14-desmethyllanosterol |
CHEBI:18364 |
4,4-dimethyl-5alpha-cholesta-8,24-dien-3beta-ol |
14-demethyllanosterol |
7448-02-4 |
4,4-dimethyl-8,24-cholestadienol |
17-(1,5-dimethylhex-4-enyl)-4,4,10,13-tetramethyl-2,3,4,5,6,7, 10,11,12,13,14,15,16,17-tetradecahydro-1h-cyclopenta[a] phenanthren-3-ol |
4,4-dimethylcholesta-8,24-dien-3-ol |
LMST01010176 |
(3s,5r,10s,13r,14r,17r)-4,4,10,13-tetramethyl-17-[(2r)-6-methylhept-5-en-2-yl]-1,2,3,5,6,7,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-ol |
4,4-dimethyl-5-alpha-cholesta-(8,24)-dien-3-beta-ol |
cholesta-8,24-dien-3-ol, 4,4-dimethyl-, (3beta,5alpha)- |
SCHEMBL188095 |
4,4-dimethyl-5alpha-cholesta-8,24-diene-3beta-ol |
Q27103032 |
Excerpt | Relevance | Reference |
---|---|---|
" Gene dosage experiments using the sphingolipid long chain sphingoid base (LCB) hydroxylase gene, SUR2, suggest that erg26-1 cells may accumulate LCB, thus placing one point of sterol regulation of sphingolipid synthesis possibly at the level of ceramide metabolism." | ( Sterol-dependent regulation of sphingolipid metabolism in Saccharomyces cerevisiae. Baudry, K; Germann, M; McDonough, V; Nickels, JT; Stukey, J; Swain, E, 2002) | 0.31 |
Role | Description |
---|---|
human metabolite | Any mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens). |
Saccharomyces cerevisiae metabolite | Any fungal metabolite produced during a metabolic reaction in Baker's yeast (Saccharomyces cerevisiae). |
mouse metabolite | Any mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus). |
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Class | Description |
---|---|
3beta-sterol | A sterol in which the hydroxy group at position 3 has beta- configuration. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 3 (50.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 3 (50.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.06) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 7 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |